The DOI matches its Crossref record.
HDAC inhibitors still need a home run, despite recent approval
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, dose-limiting adverse effects such as cardiac toxicity associated with hERG K+ channel activation are hindering their progress in the clinic [133, 134].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [133]
Citations
Cited by
Sorted by citations
HDACs and HDAC Inhibitors in Cancer Development and TherapyPreprint
Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,337
Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance
Neophytou, C. M., Trougakos, I. P., Erin, N., & Papageorgis, P. (2021) · Cancers · doi:10.3390/cancers13174363 · Cited by 392
Development of the first small molecule histone deacetylase 6 (HDAC6) degraders
Yang, K., Song, Y., Xie, H., Wu, H., Wu, Y.-T., Leisten, E. D., & Tang, W. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.05.057 · Cited by 190
Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)
Zhao, C., Dong, H., Xu, Q., & Zhang, Y. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1725470 · Cited by 151
Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
Verza, F. A., Das, U., Fachin, A. L., Dimmock, J. R., & Marins, M. (2020) · Cancers · doi:10.3390/cancers12061664 · Cited by 149
“Although HDACis are showing important activities, mainly oncological, their adverse effects and cytotoxicity are still serious and do not present selective inhibition among HDACs isoforms [216].”
Background
Metadata
- Authors
- Guha, M.
- Corresponding author
- Guha, Malini
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-04
- Volume
- 14
- Issue
- 4
- Pages
- 225-226
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2033780602
- Cited by
- 120
- References
- 0
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 8 · 2023: 9 · 2022: 8 · 2021: 14 · 2020: 18 · 2019: 11 · 2018: 9 · 2017: 16 · 2016: 12 · 2015: 7
- Type
- other
- Language
- en
- Update notices
- erratum (2015-04-30)
- Open access
- closed
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- histone deacetylase inhibitors, epigenetic regulators, cancer therapy, drug approval
- MeSH terms
- Histone Deacetylases, Humans, Multiple Myeloma, United States, United States Food and Drug Administration, Drug Approval, Epigenesis, Genetic, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
